ATE522200T1 - Aripiprazole injektionsuspension - Google Patents

Aripiprazole injektionsuspension

Info

Publication number
ATE522200T1
ATE522200T1 AT04779411T AT04779411T ATE522200T1 AT E522200 T1 ATE522200 T1 AT E522200T1 AT 04779411 T AT04779411 T AT 04779411T AT 04779411 T AT04779411 T AT 04779411T AT E522200 T1 ATE522200 T1 AT E522200T1
Authority
AT
Austria
Prior art keywords
aripiprazole
extended release
injection suspension
aripiprazole injection
injection
Prior art date
Application number
AT04779411T
Other languages
English (en)
Inventor
Josiah Brown
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34116189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE522200(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ATE522200T1 publication Critical patent/ATE522200T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04779411T 2003-08-06 2004-07-29 Aripiprazole injektionsuspension ATE522200T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/635,221 US20050032811A1 (en) 2003-08-06 2003-08-06 Methods for administering aripiprazole
PCT/US2004/024345 WO2005016262A2 (en) 2003-08-06 2004-07-29 Methods for administering aripiprazole

Publications (1)

Publication Number Publication Date
ATE522200T1 true ATE522200T1 (de) 2011-09-15

Family

ID=34116189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04779411T ATE522200T1 (de) 2003-08-06 2004-07-29 Aripiprazole injektionsuspension

Country Status (21)

Country Link
US (9) US20050032811A1 (de)
EP (2) EP2340810A1 (de)
JP (3) JP5300194B2 (de)
CN (2) CN102133171A (de)
AT (1) ATE522200T1 (de)
AU (1) AU2004264886C1 (de)
CA (1) CA2534997C (de)
CY (1) CY1111874T1 (de)
DK (1) DK1660037T3 (de)
ES (1) ES2369893T3 (de)
HR (1) HRP20110646T1 (de)
IL (1) IL173441A (de)
MX (1) MXPA06001350A (de)
NO (1) NO339816B1 (de)
NZ (1) NZ545037A (de)
PL (1) PL1660037T3 (de)
PT (1) PT1660037E (de)
SE (1) SE1660037T5 (de)
SI (1) SI1660037T1 (de)
WO (1) WO2005016262A2 (de)
ZA (1) ZA200601385B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
KR100931784B1 (ko) * 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
EP1933814A2 (de) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoteilchenförmige aripiprazol-formulierungen
CN103071209A (zh) * 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (de) 2006-07-20 2008-01-23 Helm AG Amorphes Aripiprazol und Verfahren zu dessen Herstellung
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CA2691597C (en) * 2007-06-25 2016-04-05 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
LT2170279T (lt) * 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
AU2010266018B2 (en) * 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8686009B2 (en) * 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
AR083884A1 (es) * 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
MX358344B (es) * 2011-03-18 2018-08-15 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
NZ630428A (en) * 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
EP2827868B8 (de) * 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit fettsäureestern
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
CN105078898B (zh) * 2014-05-22 2018-08-28 上海现代药物制剂工程研究中心有限公司 阿立哌唑长效缓释微粒注射剂及其制备方法
HRP20211271T1 (hr) * 2014-08-18 2022-01-07 Alkermes Pharma Ireland Limited Pripravci aripiprazolskog predlijeka
JP6591546B2 (ja) 2014-08-25 2019-10-16 アルカームス ファーマ アイルランド リミテッド 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112545995B (zh) * 2018-05-16 2024-02-23 珠海市丽珠微球科技有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
WO2021199076A1 (en) 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
CA3136727A1 (en) 2020-04-01 2021-10-07 Otsuka Pharmaceutical Co., Ltd. Methods of administering an arip-iprazole injectable preparation
KR102378590B1 (ko) * 2020-09-28 2022-03-24 (주)위바이오트리 난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN115212174B (zh) * 2022-07-18 2024-02-20 辉粒药业(苏州)有限公司 一种载阿立哌唑长效缓释微球及其制备方法
CN115969785A (zh) * 2022-12-30 2023-04-18 辰欣药业股份有限公司 一种阿立哌唑注射剂及其制备方法
KR20260004414A (ko) 2023-04-26 2026-01-08 오츠카 세이야쿠 가부시키가이샤 아리피프라졸을 사용하는 조현병 또는 양극성 장애 i형 치료를 위한 용량 개시

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5832899A (ja) * 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2002026726A2 (en) * 2000-09-26 2002-04-04 The Johns Hopkins University Antiviral compositions and methods of use
DE10048868A1 (de) * 2000-10-02 2002-04-11 Basf Ag Verfahren und Vorrichtung zur Einmischung von Zusatzstoffen während der Konditionierung von Tierfutter
JP2002191256A (ja) 2000-12-26 2002-07-09 Yoshikatsu Nakajima 水 槽
CA2662967C (en) * 2001-06-14 2012-04-10 Otsuka Pharmaceutical Co., Ltd. Medicinal composition
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
KR100931784B1 (ko) * 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
CA3136727A1 (en) * 2020-04-01 2021-10-07 Otsuka Pharmaceutical Co., Ltd. Methods of administering an arip-iprazole injectable preparation

Also Published As

Publication number Publication date
WO2005016262A2 (en) 2005-02-24
IL173441A0 (en) 2006-06-11
HK1091725A1 (en) 2007-01-26
MXPA06001350A (es) 2006-08-23
CA2534997C (en) 2011-11-01
AU2004264886A1 (en) 2005-02-24
HRP20110646T1 (hr) 2011-12-31
US8338427B2 (en) 2012-12-25
DK1660037T3 (da) 2011-12-12
US20130090343A1 (en) 2013-04-11
US8759351B2 (en) 2014-06-24
ES2369893T3 (es) 2011-12-07
EP1660037A2 (de) 2006-05-31
US20120289516A1 (en) 2012-11-15
ZA200601385B (en) 2007-02-28
SI1660037T1 (sl) 2012-05-31
PL1660037T3 (pl) 2012-03-30
US20140275109A1 (en) 2014-09-18
NO339816B1 (no) 2017-02-06
AU2004264886B2 (en) 2007-06-07
CN102133171A (zh) 2011-07-27
EP1660037A4 (de) 2008-09-24
US20090143403A1 (en) 2009-06-04
WO2005016262A3 (en) 2005-09-09
US20050032811A1 (en) 2005-02-10
NZ545037A (en) 2008-10-31
SE1660037T5 (de) 2015-09-15
CA2534997A1 (en) 2005-02-24
EP1660037B1 (de) 2011-08-31
US20210346282A1 (en) 2021-11-11
JP2014001250A (ja) 2014-01-09
NO20060638L (no) 2006-04-26
US8338428B2 (en) 2012-12-25
JP2007501236A (ja) 2007-01-25
AU2004264886C1 (en) 2021-06-03
JP5764634B2 (ja) 2015-08-19
CN1845721A (zh) 2006-10-11
US20230218506A1 (en) 2023-07-13
PT1660037E (pt) 2011-10-24
CY1111874T1 (el) 2015-11-04
US20180169005A1 (en) 2018-06-21
US20190231679A1 (en) 2019-08-01
IL173441A (en) 2013-04-30
JP5300194B2 (ja) 2013-09-25
EP2340810A1 (de) 2011-07-06
JP2010248258A (ja) 2010-11-04
JP5453194B2 (ja) 2014-03-26

Similar Documents

Publication Publication Date Title
DK1660037T3 (da) Aripiprazol-injektionssuspension
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
ATE450252T1 (de) Arzneimittel-mikroteilchen
WO2006002365A3 (en) Microparticles with high loadings of a bioactive agent
ATE432689T1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
BRPI0620063B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
UA88300C2 (ru) Гидрогелевые композиции, которые содержат интерферон
NO20076053L (no) Pyrazolpyrimidinderivat for behandling og forebygging av leversykdom
MY151468A (en) Controlled release solid preparation
DE60140997D1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung
BR0013283A (pt) Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
EA200700484A1 (ru) Фармацевтическая композиция толтеродина с пролонгированным высвобождением
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
EP1634585A4 (de) Arzneimittel enthaltendes mikroteilchen mit verzögerter freisetzung, verfahren zu seiner herstellung und das mikroteilchen enthaltende zubereitung
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
ATE334658T1 (de) Arzneimittel zur verabreichung an schleimhäute
SE0203817D0 (sv) New composition
BR0315231A (pt) Compostos com base em glicose com afinidade para p-seletina
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
BRPI0510858A (pt) composição, composto e método para administrar um agente biologicamente ativo a um animal necessitando o mesmo
ATE429905T1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1660037

Country of ref document: EP